The Role of CDKs Inhibitors in Cancer Immunotherapy

Hallmarks of cancer are uncontrollable proliferation and suppressed immune microenvironment. Cyclin-dependent kinases (CDKs) are family of protein kinases first identified for their role in the regulation of cell cycle and transcription. Increasing recognition of CDKs inhibitors, which trigger immunogenic responses in cancer treatment, helps to maintain the durable clinical benefits. In this minireview, we will focus on recent studies about the immunogenic effects of CDK inhibitors, the mechanism of resistance and the current clinical trials in cancer treatment.